Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 14/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | PREP | P48147 | 4/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703880 | 1.00 | DPP4 (0.41) | DPP4DPP7KCNH2PREPDPP8 | |
| SCHEMBL28192422 | 0.79 | DPP4 (0.37) | DPP4DPP7KCNH2PREP | |
| SCHEMBL28650978 | 0.79 | DPP4 (0.37) | DPP4DPP7KCNH2PREP | |
| SCHEMBL28655579 | 0.79 | DPP4 (0.37) | DPP4DPP7KCNH2PREP | |
| SCHEMBL4701002 | 0.75 | PREP (0.53) | DPP4DPP7KCNH2PREPDPP8 | |
| SCHEMBL4703882 | 0.75 | PREP (0.53) | DPP4DPP7KCNH2PREPDPP8 | |
| SCHEMBL4700999 | 0.75 | PREP (0.53) | DPP4DPP7KCNH2PREPDPP8 | |
| SCHEMBL4071682 | 0.72 | PREP (0.49) | DPP4PREP | |
| SCHEMBL4071686 | 0.72 | PREP (0.49) | DPP4PREP | |
| SCHEMBL4698101 | 0.70 | DPP4 (0.78) | DPP4DPP7KCNH2DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385508-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7026316-B2 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040106656-A1 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106656-A1 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885KCNH2 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.